StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) shareholders

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.49+0.62 (+2.22%)

Close on Nov 17, 2026Market cap $4.55BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
97.6%
156M of 160M shares
Institutional holders
300
49 new, 42 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 185 sales
Net sold $131.75M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Viking Global Investors LP
Joint filing with Halvorsen Ole Andreas (18.80%), Shabet Rose Sharon (18.80%) and 4 more
29,993,70818.80%13G (passive) amendmentMar 31, 2026
BlackRock, Inc.11,992,4487.90%13G (passive) amendmentDec 31, 2025
Catherine D. Wood
Joint filing with ARK Investment Management LLC (5.20%)
7,732,5705.20%13G (passive)Mar 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ADPTValueChange% of portfolio
Viking Global Investors LP29,993,70818.79%$643.37M–1.83%
BlackRock, Inc.15,139,1599.49%$324.73M+1,836,1340.00%
Vanguard Capital Management LLC6,403,5874.01%$137.36M+309,4430.00%
Wellington Management Group Llp5,911,3663.70%$126.80M+2,053,9440.02%
Vanguard Portfolio Management LLC5,476,2313.43%$117.47M+984,7570.01%
D. E. Shaw & Co., Inc.4,625,8592.90%$99.22M+2,660,2490.05%
Westfield Capital Management Co LP4,267,6452.67%$91.54M−1,169,0730.30%
Geode Capital Management, LLC3,641,8372.28%$78.13M+5,7830.00%
State Street Corp3,458,3882.17%$74.18M+231,1430.00%
Invesco Ltd.3,094,0111.94%$66.37M−1,356,0550.01%
Goldman Sachs Group Inc2,984,2271.87%$64.01M−257,8500.01%
Price T Rowe Associates Inc /Md/2,665,3081.67%$57.17M+1,099,0950.01%
Driehaus Capital Management LLC2,527,7031.58%$54.22M+777,1020.31%
Arrowstreet Capital, Limited Partnership2,524,6201.58%$54.15M+529,4180.02%
Lord, Abbett & Co. LLC2,474,8141.55%$53.09M−1,061,2890.15%
Nuveen, LLC2,366,1551.48%$50.75M+1,061,9950.01%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.2,182,3261.37%$46.81M−505,7550.05%
Fred Alger Management, LLC2,092,2841.31%$44.88M+29,1380.15%
ARK Investment Management LLC2,090,3061.31%$44.84M−2,6630.29%
Nomura Asset Management International Inc.1,889,1881.18%$40.52M+8,0050.06%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026300156M97.6%49 / 10989 / 4224M20M
Q1 2026298152M95.2%57 / 10196 / 3834M21M
Q4 2025283150M94.2%52 / 10092 / 3829M24M
Q3 2025271146M91.3%55 / 9381 / 2520M23M
Q2 2025242149M93.1%46 / 9263 / 2622M29M
Q1 2025225155M97.1%40 / 7367 / 1929M17M
Q4 2024207143M89.8%46 / 6745 / 2313M13M
Q3 2024187144M90.2%32 / 6545 / 2023M17M
Q2 2024177150M93.8%25 / 7045 / 3725M19M
Q1 2024190144M90.3%28 / 5768 / 3714M14M
Q4 2023200145M90.8%38 / 5972 / 2613M9M
Q3 2023190141M88.5%16 / 5975 / 3415M8M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

275 funds held ADPT in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ADPTValue% of fundAs of
Vanguard Total Stock Market Index Fund4,834,3093.03%$103.70M0.00%Jun 30, 2026
iShares Russell 2000 ETF3,955,5652.48%$84.85M0.10%Jun 30, 2026
ARK Genomic Revolution ETF1,774,7561.11%$40.06M2.57%Jul 31, 2026
Vanguard Small-Cap Index Fund1,742,8541.09%$37.38M0.02%Jun 30, 2026
Fidelity Small Cap Index Fund1,684,9981.06%$38.03M0.11%Jul 31, 2026
Alger Small Cap Focus Fund1,494,2140.94%$33.72M3.95%Jul 31, 2026
iShares Russell 2000 Growth ETF1,422,5850.89%$30.51M0.20%Jun 30, 2026
Vanguard Extended Market Index Fund1,415,6210.89%$30.37M0.03%Jun 30, 2026
Oberweis Micro-Cap Fund1,215,6000.76%$26.07M1.61%Jun 30, 2026
Lord Abbett Developing Growth Fund Inc1,194,2460.75%$26.95M1.21%Jul 31, 2026
Invesco Main Street Small Cap Fund1,102,4170.69%$23.65M0.89%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1,101,6370.69%$23.63M0.24%Jun 30, 2026
iShares Biotechnology ETF1,094,7150.69%$23.48M0.26%Jun 30, 2026
Nomura Small Cap Growth Fund1,084,4680.68%$23.26M1.99%Jun 30, 2026
SmallCap Fund1,031,0600.65%$23.27M1.12%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Chad M. RobinsCEO and Chairman, Director2,930,5181.84%Nov 12, 2026
Julie RubinsteinPresident and COO377,8020.24%Nov 13, 2026
Susan BobulskyChief Commercial Officer, MRD387,4750.24%Nov 13, 2026
Francis LoChief People Officer223,3670.14%Oct 5, 2026
Harlan S. RobinsChief Scientific Officer2,104,4581.32%Jul 23, 2026
Sharon BenzenoChief Commercial Ofc Imm Med299,5320.19%Jun 30, 2026
Kyle PiskelChief Financial Officer256,7250.16%May 20, 2026
Katey Einterz OwenDirector66,1000.04%Sep 2, 2026
Robert HershbergDirector77,3470.05%Aug 20, 2026
Peter M. NeupertDirector255,3150.16%Aug 19, 2026
Michelle Renee GriffinDirector15,6250.01%Jun 29, 2026
Michael J. PelliniDirector69,6900.04%Mar 6, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Julie Rubinstein
President and COO
Nov 13, 2026Sale(10b5-1 plan)−11,466$28.93$331.71K377,802
Julie Rubinstein
President and COO
Nov 13, 2026Option exercise+11,466$12.14$139.20K389,268
Julie Rubinstein
President and COO
Nov 12, 2026Sale(10b5-1 plan)−11,881$29.40$349.30K377,802
Julie Rubinstein
President and COO
Nov 12, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Nov 11, 2026Sale(10b5-1 plan)−6,898$31.22$215.36K377,802
Julie Rubinstein
President and COO
Nov 11, 2026Sale(10b5-1 plan)−4,983$30.29$150.94K384,700
Julie Rubinstein
President and COO
Nov 11, 2026Option exercise+11,881$12.14$144.24K389,683
Susan Bobulsky
Chief Commercial Officer, MRD
Nov 11, 2026Sale(10b5-1 plan)−1,875$32.00$60.00K387,475
Julie Rubinstein
President and COO
Nov 10, 2026Sale(10b5-1 plan)−1,900$30.41$57.78K377,802
Julie Rubinstein
President and COO
Nov 10, 2026Sale(10b5-1 plan)−9,981$29.35$292.94K379,702
Julie Rubinstein
President and COO
Nov 10, 2026Option exercise+11,881$12.14$144.24K389,683
Chad M. Robins
CEO and Chairman, Director
Nov 9, 2026Gift−100,000––2,080,518
Julie Rubinstein
President and COO
Nov 9, 2026Sale(10b5-1 plan)−2,400$30.58$73.39K377,802
Julie Rubinstein
President and COO
Nov 9, 2026Sale(10b5-1 plan)−8,381$30.15$252.69K380,202
Julie Rubinstein
President and COO
Nov 9, 2026Sale(10b5-1 plan)−1,100$28.87$31.76K388,583
Julie Rubinstein
President and COO
Nov 9, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Nov 6, 2026Sale(10b5-1 plan)−3,481$27.88$97.05K377,802
Julie Rubinstein
President and COO
Nov 6, 2026Sale(10b5-1 plan)−8,400$27.32$229.49K381,283
Julie Rubinstein
President and COO
Nov 6, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Nov 5, 2026Sale(10b5-1 plan)−500$27.70$13.85K377,802
Julie Rubinstein
President and COO
Nov 5, 2026Sale(10b5-1 plan)−5,455$26.88$146.63K378,302
Julie Rubinstein
President and COO
Nov 5, 2026Sale(10b5-1 plan)−5,926$26.10$154.67K383,757
Julie Rubinstein
President and COO
Nov 5, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Nov 4, 2026Sale(10b5-1 plan)−7,881$26.60$209.63K377,802
Julie Rubinstein
President and COO
Nov 4, 2026Sale(10b5-1 plan)−4,000$25.78$103.12K385,683
Julie Rubinstein
President and COO
Nov 4, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Nov 3, 2026Sale(10b5-1 plan)−11,881$25.98$308.67K377,802
Julie Rubinstein
President and COO
Nov 3, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Nov 2, 2026Sale(10b5-1 plan)−2,585$26.34$68.09K377,802
Julie Rubinstein
President and COO
Nov 2, 2026Sale(10b5-1 plan)−9,296$25.23$234.54K380,387
Julie Rubinstein
President and COO
Nov 2, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 30, 2026Sale(10b5-1 plan)−2,395$27.45$65.74K377,802
Julie Rubinstein
President and COO
Oct 30, 2026Sale(10b5-1 plan)−9,486$26.55$251.85K380,197
Julie Rubinstein
President and COO
Oct 30, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 29, 2026Sale(10b5-1 plan)−11,881$28.27$335.88K377,802
Julie Rubinstein
President and COO
Oct 29, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 28, 2026Sale(10b5-1 plan)−200$28.90$5.78K377,802
Julie Rubinstein
President and COO
Oct 28, 2026Sale(10b5-1 plan)−11,681$28.44$332.21K378,002
Julie Rubinstein
President and COO
Oct 28, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 27, 2026Sale(10b5-1 plan)−8,881$27.53$244.49K377,802
Julie Rubinstein
President and COO
Oct 27, 2026Sale(10b5-1 plan)−3,000$26.58$79.74K386,683
Julie Rubinstein
President and COO
Oct 27, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 26, 2026Sale(10b5-1 plan)−3,378$26.30$88.84K377,802
Julie Rubinstein
President and COO
Oct 26, 2026Sale(10b5-1 plan)−8,503$25.94$220.57K381,180
Julie Rubinstein
President and COO
Oct 26, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 23, 2026Sale(10b5-1 plan)−7,381$25.28$186.59K377,802
Julie Rubinstein
President and COO
Oct 23, 2026Sale(10b5-1 plan)−4,500$24.50$110.25K385,183
Julie Rubinstein
President and COO
Oct 23, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 22, 2026Sale(10b5-1 plan)−1,700$25.29$42.99K377,802
Julie Rubinstein
President and COO
Oct 22, 2026Sale(10b5-1 plan)−10,181$24.38$248.21K379,502
Julie Rubinstein
President and COO
Oct 22, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 21, 2026Sale(10b5-1 plan)−5,882$25.57$150.40K377,802
Julie Rubinstein
President and COO
Oct 21, 2026Sale(10b5-1 plan)−5,999$25.25$151.47K383,684
Julie Rubinstein
President and COO
Oct 21, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 20, 2026Sale(10b5-1 plan)−100$24.85$2.49K377,802
Julie Rubinstein
President and COO
Oct 20, 2026Sale(10b5-1 plan)−11,781$24.53$288.99K377,902
Julie Rubinstein
President and COO
Oct 20, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 19, 2026Sale(10b5-1 plan)−11,881$24.05$285.74K377,802
Julie Rubinstein
President and COO
Oct 19, 2026Option exercise+11,881$12.14$144.24K389,683
Julie Rubinstein
President and COO
Oct 16, 2026Sale(10b5-1 plan)−300$25.45$7.64K377,802

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
9.30%
11M shares short
Days to cover
6.1
At 2M shares a day
Change since last report
-4.3%
From 12M shares
Short volume, 20 days
46.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Adaptive Biotechnologies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,479 shares on Sep 8, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Susan Bobulsky
Officer
Oct 6, 20266,444$192.29KOct 6, 2026Restricted Stock Units
Julie Rubinstein
Officer
Oct 1, 2026379,777$10.98MOct 1, 2026Exercise of Stock Options
Francis Lo
Officer
Sep 16, 2026142,198$3.79MSep 16, 2026Exercise of Stock Options
Susan Bobulsky
Officer
Sep 15, 20261,195$29.61KSep 15, 2026Restricted Stock Units
Katherine E Owen
Director
Aug 26, 20269,615$249.99KAug 26, 2026Restricted Stock
Harlan S. Robins
Former Officer
Aug 20, 2026402,160$10.23MAug 20, 2026Acquired as compensation -- Stock Options
Harlan S. Robins
Former Officer
Aug 19, 2026215,632$5.50MAug 19, 2026Acquired as compensation -- Stock Options
Robert Hershberg
Director
Aug 18, 202630,664$748.30KAug 18, 2026Stock Option Exercise
Chad M. Robins
Officer
Aug 18, 2026278,676$6.84MAug 18, 2026Acquired as compensation -- Stock Options
Harlan S. Robins
Former Officer
Aug 18, 2026261,044$6.41MAug 18, 2026Acquired as compensation -- Stock Options
Peter M. Neupert
Director
Aug 17, 2026124,690$3.14MAug 17, 2026Stock Option Exercise
Chad M. Robins
Officer
Aug 17, 2026321,324$7.96MAug 17, 2026Acquired as compensation -- Stock Options
Harlan S. Robins
Former Officer
Aug 17, 2026300,992$7.46MAug 17, 2026Acquired as compensation -- Performance Awards
Susan Bobulsky
Officer
Aug 10, 20263,000$74.79KAug 10, 2026Restricted Stock Units
Susan Bobulsky
Officer
Jul 30, 20261,299$29.31KJul 30, 2026Restricted Stock Units

See a number that looks wrong?